Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × cobomarsen × Clear all
NCT02580552 2020-11-23

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

miRagen Therapeutics, Inc.

Phase 1 Completed
66 enrolled
DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡